Department of Bioengineering and Therapeutic Sciences professor Nadav Ahituv is part of a team of researchers using the gene editing technology CRISPR to deprive tumors of nutrition.
Here are some of the standout moments from 2024 that drove our commitment to leadership in research, education, patient care, and innovation, all aimed at expanding knowledge and enhancing health worldwide.
The director of the UCSF Institute for Human Genetics (IHG) is being recognized for his lab’s work investigating gene regulatory elements––their relationship to human diversity and disease and their utilization for gene therapy.
The Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium has been awarded a $30.8M grant over five years to research the most effective treatment options for future clinical testing.
Academia, government, and industry come together to address today’s most pressing issues in the regulation of medical products, from diversity in clinical trials to misinformation.
This year’s Seed Awards will support projects ranging from the discovery sciences and patient care to sustainability and diversity, equity, and inclusion
